Search

Your search keyword '"Tanis, Bea C."' showing total 34 results
Start Over Author "Tanis, Bea C."
34 results on '"Tanis, Bea C."'

1. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Author

Zweegman, Sonja, van der Holt, Bronno, Mellqvist, Ulf-Henrik, Salomo, Morten, Bos, Gerard M.J., Levin, Mark-David, Visser-Wisselaar, Heleen, Hansson, Markus, van der Velden, Annette W.G., Deenik, Wendy, Gruber, Astrid, Coenen, Juleon L.L.M., Plesner, Torben, Klein, Saskia K., Tanis, Bea C., Szatkowski, Damian L., Brouwer, Rolf E., Westerman, Matthijs, Leys, M.(Rineke) B.L., Sinnige, Harm A.M., Haukås, Einar, van der Hem, Klaas G., Durian, Marc F., Mattijssen, E.(Vera)J.M., van de Donk, Niels W.C.J., Stevens-Kroef, Marian J.P.L., Sonneveld, Pieter, and Waage, Anders

Published
2016
Full Text
View/download PDF

5. Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era

Author

Wensink, G. Emerens, primary, Elferink, Marloes A. G., additional, May, Anne M., additional, Mol, Linda, additional, Hamers, Patricia A. H., additional, Bakker, Sandra D., additional, Creemers, Geert-Jan, additional, de Groot, Jan Willem B., additional, de Klerk, Gerty J., additional, Haberkorn, Brigitte C. M., additional, Haringhuizen, Annebeth W., additional, Hoekstra, Ronald, additional, Hunting, J. Cornelis B., additional, Kerver, Emile D., additional, Mathijssen-van Stein, Danielle, additional, Polée, Marco B., additional, Pruijt, Johannes F. M., additional, Quarles van Ufford-Mannesse, Patricia, additional, Radema, Sandra, additional, Rietbroek, Ronald C., additional, Simkens, Lieke H. J., additional, Tanis, Bea C., additional, ten Bokkel Huinink, Daan, additional, Tjin-A-Ton, Manuel L. R., additional, Tromp-van Driel, Cathrien S., additional, Troost, Monique M., additional, van de Wouw, Agnes J., additional, van den Berkmortel, Franchette W. P. J., additional, van der Pas, Anke J. M., additional, van der Velden, Ankie M. T., additional, van Dijk, Marjan A., additional, van Dodewaard-de Jong, Joyce M., additional, van Druten, Edith B., additional, van Voorthuizen, Theo, additional, Jan Veldhuis, Gerrit, additional, Verheul, Henk M. W., additional, Vestjens, Hanneke J. H. M. J., additional, Vincent, Jeroen, additional, Kranenburg, Onno W., additional, Punt, Cornelis J. A., additional, Vink, Geraldine R., additional, Roodhart, Jeanine M. L., additional, and Koopman, Miriam, additional

Published
2020
Full Text
View/download PDF

6. Oral contraceptive and the risk of myocardial infarction

Author

Tanis, Bea C., Bosch, Maurice A.A.J. van den, Kemmeren, Jeanet M., Cats, Volkert Manger, Helmerhorst, Frans M., Algra, Ale, Graaf, Yolanda van der, and Rosendaal, Frits R.

Subjects
Heart attack -- Risk factors, Oral contraceptives -- Adverse and side effects
Abstract

Women who use second-generation oral contraceptives have twice the risk of having a heart attack as women who do not use oral contraceptives, according to a study of 1,173 women. Women can lower this risk by using third-generation oral contraceptives.

Published
2001

7. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial

Author

Kurk, Sophie A., primary, Peeters, Petra H. M., additional, Dorresteijn, Bram, additional, de Jong, Pim A., additional, Jourdan, Marion, additional, Creemers, Geert‐Jan M., additional, Erdkamp, Frans L. G., additional, de Jongh, Felix E., additional, Kint, Peter A. M., additional, Poppema, Boelo J., additional, Radema, Sandra A., additional, Simkens, Lieke H. J., additional, Tanis, Bea C., additional, Tjin‐A‐Ton, Manuel L. R., additional, Van Der Velden, Ankie, additional, Punt, Cornelis J. A., additional, Koopman, Miriam, additional, and May, Anne M., additional

Published
2019
Full Text
View/download PDF

12. High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma

Author

Schrader, Anne M.R., Jansen, Patty M., Willemze, Rein, Vermeer, Maarten H., Cleton-Jansen, Anne-Marie, Somers, Sebastiaan F., Veelken, Hendrik, van Eijk, Ronald, Kraan, Willem, Kersten, Marie José, van den Brand, Michiel, Stevens, Wendy B.C., de Jong, Daphne, Abdul Hamid, Myrurgia, Tanis, Bea C., Posthuma, Eduardus F.M., Nijland, Marcel, Diepstra, Arjan, Pals, Steven T., Cleven, Arjen H.G., and Vermaat, Joost S.P.

Published
2018
Full Text
View/download PDF

15. Novel risk factors for peripheral arterial disease in young women

Author

Bloemenkamp, Daisy G.M., Bosch, Maurice A.A.J. van den, Mali, Willem P.Th.M., Tanis, Bea C., Rosendaal, Frits R., Kemmeren, Jeanet M., Algra, Ale, Visseren, Frank L.J., and Graaf, Yolanda van der

Subjects
Peripheral vascular diseases -- Risk factors, Young women -- Diseases, Health, Health care industry
Published
2002

17. Dutch women with a low birth weight have an increased risk of myocardial infarction later in life: a case control study

Author

Rosendaal Frits R, Hage Ronella M, Kapiteijn Kitty, Tanis Bea C, and Helmerhorst Frans M

Subjects
Gynecology and obstetrics, RG1-991
Abstract

Abstract Background To investigate whether low birth weight increases the risk of myocardial infarction later in life in women. Methods Nationwide population-based case-control study. Patients and controls: 152 patients with a first myocardial infarction before the age of 50 years in the Netherlands. 568 control women who had not had a myocardial infarction stratified for age, calendar year of the index event, and area of residence. Results Birth weight in the patient group was significantly lower than in control women (3214 vs. 3370 gram, mean difference -156.3 gram (95%CI -9.5 to -303.1). The odds ratio for myocardial infarction, associated with a birth weight lower than 3000 gram (20th percentile in controls) compared to higher than 3000 gram was 1.7 (95%CI 1.1–2.7), while the odds ratio for myocardial infarction for children with a low birth weight (< 2000 g) compared to a birth weight ≥ 2000 g was 2.4 (95%CI 1.0 – 5.8). Both figures did not change after adjustment for putative confounders (age, education level, body mass index, waist-hip ratio, hypertension, diabetes, hypercholesterolemia, smoking, and family history of cardiovascular disease). Conclusions Low birth weight is associated with an increased risk of myocardial infarction before age of 50 in Dutch women.

Published
2005
Full Text
View/download PDF

18. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.

Author

Kurk, Sophie A., Peeters, Petra H. M., Dorresteijn, Bram, Jong, Pim A., Jourdan, Marion, Creemers, Geert‐Jan M., Erdkamp, Frans L. G., Jongh, Felix E., Kint, Peter A. M., Poppema, Boelo J., Radema, Sandra A., Simkens, Lieke H. J., Tanis, Bea C., Tjin‐A‐Ton, Manuel L. R., Van Der Velden, Ankie, Punt, Cornelis J. A., Koopman, Miriam, and May, Anne M.

Subjects
SKELETAL muscle, COLORECTAL cancer, METASTASIS, SECONDARY analysis, BODY mass index
Abstract

Background: Low skeletal muscle index (SMI) in metastatic colorectal cancer (mCRC) patients is associated with poor outcomes. The prognostic impact of SMI changes during consecutive palliative systemic treatments is unknown. Methods: This is a retrospective analysis of the phase 3 CAIRO3 study. The CAIRO3 study randomized 557 patients between maintenance capecitabine + bevacizumab (CAP‐B) or observation, after six cycles capecitabine + oxaliplatin + bevacizumab (CAPOX‐B). Upon first disease progression (PD1), CAPOX‐B was reintroduced until second progression (PD2). SMI was assessed by computed tomography (CT) (total 1355 scans). SMI and body mass index (BMI) changes were analyzed for three time‐periods; p1: during initial CAPOX‐B, p2: randomization to PD1, and p3: PD1 to PD2. The association between absolute and change in SMI and BMI (both per 1 standard deviation) during p1‐p3, with PD1, PD2, and survival was studied by Cox regression models. Results: This analysis included 450 of the 557 patients randomized in the CAIRO3 study. Mean SMI decreased during p1: mean −0.6 SMI units [95% CI −1.07;‐0.26] and p3: −2.2 units [−2.7;‐1.8], whereas during p2, SMI increased + 1.2 units [0.8‐1.6]. BMI changes did not reflect changes in SMI. SMI loss during p2 and p3 was significantly associated with shorter survival (HR 1.19 [1.09‐1.35]; 1.54 [1.31‐1.79], respectively). Sarcopenia at PD1 was significantly associated with early PD2 (HR 1.40 [1.10‐1.70]). BMI loss independent of SMI loss was only associated with shorter overall survival during p3 (HR 1.35 [1.14‐1.63]). Conclusions: In mCRC patients, SMI loss during palliative systemic treatment was related with early disease progression and reduced survival. BMI did not reflect changes in SMI and could not identify patients at risk of poor outcome during early treatment lines. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

19. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial

Author

Cats, Annemieke, primary, Jansen, Edwin P M, additional, van Grieken, Nicole C T, additional, Sikorska, Karolina, additional, Lind, Pehr, additional, Nordsmark, Marianne, additional, Meershoek-Klein Kranenbarg, Elma, additional, Boot, Henk, additional, Trip, Anouk K, additional, Swellengrebel, H A Maurits, additional, van Laarhoven, Hanneke W M, additional, Putter, Hein, additional, van Sandick, Johanna W, additional, van Berge Henegouwen, Mark I, additional, Hartgrink, Henk H, additional, van Tinteren, Harm, additional, van de Velde, Cornelis J H, additional, Verheij, Marcel, additional, Van Coevorden, Frits, additional, Vanhoutvin, Steven, additional, Hulshof, Maarten CCM, additional, Loosveld, Olaf JL, additional, Ten Tije, A (Bert) Jan, additional, Erdkamp, Frans LG, additional, Warmerdam, Fabienne ARM, additional, Van der Peet, Donald L, additional, Verheul, Henk MW, additional, Boerma, Djamila, additional, Los, Maartje, additional, Slot, Annerie, additional, Houtsma, Danny, additional, Portielje, Johanna EA, additional, Blaisse, Reinoud JB, additional, Spillenaar Bilgen, Ernst Jan, additional, Polée, Marco B, additional, Geenen, Maud M, additional, Braak, Jeffrey PBM, additional, Neelis, Karen J, additional, Slingerland, Marije, additional, Jansen, Rob LH, additional, Buijsen, Jeroen, additional, Beeker, Aart, additional, Eijsbouts, Quirijn AJ, additional, Van Riel, Johanna MGH, additional, Rozema, Tom, additional, Van Spronsen, Dick Johan, additional, Meerum Terwogt, Jetske M, additional, Tanis, Bea C, additional, Van der Torren-Conze, Adelheid ME, additional, Van Hilligersberg, Richard, additional, Koopman, Miriam, additional, Den Boer, Marien O, additional, Creemers, Geert-Jan, additional, Van der Sangen, Maurice, additional, Rentinck, Marjolein EM, additional, Van den Berg, H Pieter, additional, Jonkers, Ge JPM, additional, Grootenboers, Diane, additional, Vulink, Annelie JE, additional, Hovenga, Sjoerd, additional, Van der Mijle, Huub CJ, additional, Baars, Arnold, additional, Haringhuizen, Annebeth W, additional, Appels, Marije IE, additional, Rietbroek, Ron C, additional, Hendriksen, Ellen M, additional, Legdeur, Marie-Cecile JC, additional, Ten Bokkel Huinink, Daan, additional, Van Dobbenburgh, O Aart, additional, Smit, Jitty M, additional, Van Bochove, Aart, additional, Veldhuis, Gerrit-Jan, additional, Muller, Erik W, additional, Bonenkamp, J (Han) J, additional, Braam, Pètra M, additional, De Boer, Jaap, additional, Van Halteren, Henk K, additional, Valster, Fransje AA, additional, Imholz, Alex LT, additional, Van Dijk, Marjan A, additional, Van der Gaast, Ate, additional, Otten, J (Hans)-Martin MB, additional, Ceha, Heleen M, additional, Glimelius, Bengt, additional, Lagerbäck, Cecillia, additional, Perman, Mats, additional, Johnsson, Anders, additional, Borg, David, additional, Nielsen, Niels H, additional, Piwowar, Andrzej, additional, Elmlund, Mattias, additional, Hörberg, Helene, additional, Edlund, Per, additional, Johansson, Bengt, additional, Flygare, Petra, additional, and Jespersen, Marie Louise, additional

Published
2018
Full Text
View/download PDF

20. Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

Author

Broijl, Annemiek, primary, Kersten, Marie-José, additional, Alemayehu, Wendimagegn Ghidey, additional, Levin, Mark-David, additional, de Weerdt, Okke, additional, Vellenga, Edo, additional, Meijer, Ellen, additional, Wittebol, Shulamit, additional, Tanis, Bea C., additional, Cornelisse, Petra B., additional, Stevens-Kroef, Marian, additional, Bos, Gerard M.J., additional, Wijermans, Pierre W., additional, Lokhorst, Henk, additional, and Sonneveld, Pieter, additional

Published
2015
Full Text
View/download PDF

23. High prevalence of MYD88and CD79Bmutations in intravascular large B-cell lymphoma

Author

Schrader, Anne M.R., Jansen, Patty M., Willemze, Rein, Vermeer, Maarten H., Cleton-Jansen, Anne-Marie, Somers, Sebastiaan F., Veelken, Hendrik, van Eijk, Ronald, Kraan, Willem, Kersten, Marie José, van den Brand, Michiel, Stevens, Wendy B.C., de Jong, Daphne, Abdul Hamid, Myrurgia, Tanis, Bea C., Posthuma, Eduardus F.M., Nijland, Marcel, Diepstra, Arjan, Pals, Steven T., Cleven, Arjen H.G., and Vermaat, Joost S.P.

Published
2018
Full Text
View/download PDF

24. Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly.

Author

Aaldriks, Ab A., Maartense, Ed, Nortier, Hans J. W. R., van der Geest, Lydia G. M., le Cessie, Saskia, Tanis, Bea C., Portielje, Johanneke E. A., Ypma, Paula, and Giltay, Erik J.

Subjects
TUMOR risk factors, AGE distribution, GERIATRIC assessment, CANCER chemotherapy, FRAIL elderly, MORTALITY, MULTIVARIATE analysis, PROGNOSIS, QUESTIONNAIRES, RESEARCH funding, LOGISTIC regression analysis, PILOT projects, PROPORTIONAL hazards models, DATA analysis software, ODDS ratio
Abstract

Background.Comprehensive geriatric assessment (CGA) is a multidimensional method to detect frailty in elderly patients. Time saving could be accomplished by identifying those individual items that classify elderly cancer patients at risk for feasibility of chemotherapy and for mortality. Material and methods.Patients older than 70 years of age were assessed before the first chemotherapy administration. GA consisted of the Mini Nutritional Assessment (MNA), Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), Groningen Frailty Indicator (GFI) and Mini Mental State Examination (MMSE). Predictive individual items for feasibility of chemotherapy and mortality were entered in the multivariable logistic regression and Cox-regression models, and a three-item sum scale was constructed: the Geriatric Prognostic Index (GPI). Results.The 494 patients had a median age of 75 years (range 70–92 years). The majority of the patients had malignancies of the digestive tract (41.7%) followed by hematological tumors (22.3%). Three items of the MNA (‘psychological distress or acute disease in the past three months’, ‘neuropsychological problems’ and ‘using > 3 prescript drugs’) independently predicted for feasibility of chemotherapy. Two items of the MNA and one of the GFI (‘declining food intake in past 3 months’, ‘using > 3 prescript drugs’, and ‘dependence in shopping’) independently predicted for mortality. In comparison with patients without any positive item on the three-item GPI, patients with one, two or three positive items had hazard ratios (HRs) of 1.58, 2.32, and 5.58, respectively (all p < 0.001). Conclusions.With only three items of the MNA, feasibility of chemotherapy can be predicted. The three-item GPI may help to identify elderly cancer patients at elevated risk for mortality. [ABSTRACT FROM PUBLISHER]

Published
2016
Full Text
View/download PDF

26. Increased pregnancy loss in young women with aortoiliac disease

Author

van den Bosch, Maurice A.A.J, primary, Mali, Willem P.Th.M, additional, Bloemenkamp, Daisy G.M, additional, Eikelboom, Bert C, additional, Kemmeren, Jeanet M, additional, Tanis, Bea C, additional, Algra, Ale, additional, Rosendaal, Frits R, additional, and van der Graaf, Yolanda, additional

Published
2002
Full Text
View/download PDF

27. Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus infections and the risk of peripheral arterial disease in young women

Author

Bloemenkamp, Daisy G.M., primary, Mali, Willem P.Th.M., additional, Tanis, Bea C., additional, Rosendaal, Frits R., additional, van den Bosch, Maurice A.A.J., additional, Kemmeren, Jeanet M., additional, Algra, Ale, additional, Ossewaarde, Jacobus M., additional, Visseren, Frank L.J., additional, van Loon, Anton M., additional, and van der Graaf, Yolanda, additional

Published
2002
Full Text
View/download PDF

28. Oral Contraceptives and the Risk of Myocardial Infarction

Author

Tanis, Bea C., primary, van den Bosch, Maurice A. A. J., additional, Kemmeren, Jeanet M., additional, Cats, Volkert Manger, additional, Helmerhorst, Frans M., additional, Algra, Ale, additional, van der Graaf, Yolanda, additional, and Rosendaal, Frits R., additional

Published
2002
Full Text
View/download PDF

29. Multicenter Phase II Study of Spiroplatin

Author

Tanis, Bea C., primary, Vermorken, Jan B., additional, ten Bokkel Huinink, Wim W., additional, van Oosterom, Allan T., additional, Splinter, Ted A.W., additional, Vendrik, Ko J., additional, Sleijfer, Dirk T.H., additional, Van der Burgs, Maria E.L., additional, Van der Putten, Erie, additional, and Pinedo, Herbert M., additional

Published
1992
Full Text
View/download PDF

30. Phase I study of spiroplatin

Author

Tanis, Bea C., primary, Vermorken, Jan B., additional, Ten Bokkel Huinink, Wim W., additional, Klein, Ina, additional, Gall, Helen, additional, Van Oosterom, Allan T., additional, Simonetti, Godelaine, additional, Gordon McVie, J., additional, Van Der Vijgh, Wim J.F., additional, and Pinedo, Herbert M., additional

Published
1991
Full Text
View/download PDF

32. Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.

Author

Wensink GE, Elferink MAG, May AM, Mol L, Hamers PAH, Bakker SD, Creemers GJ, de Groot JWB, de Klerk GJ, Haberkorn BCM, Haringhuizen AW, Hoekstra R, Hunting JCB, Kerver ED, Mathijssen-van Stein D, Polée MB, Pruijt JFM, Quarles van Ufford-Mannesse P, Radema S, Rietbroek RC, Simkens LHJ, Tanis BC, Ten Bokkel Huinink D, Tjin-A-Ton MLR, Tromp-van Driel CS, Troost MM, van de Wouw AJ, van den Berkmortel FWPJ, van der Pas AJM, van der Velden AMT, van Dijk MA, van Dodewaard-de Jong JM, van Druten EB, van Voorthuizen T, Jan Veldhuis G, Verheul HMW, Vestjens HJHMJ, Vincent J, Kranenburg OW, Punt CJA, Vink GR, Roodhart JML, and Koopman M

Subjects
Adult, Aged, Colorectal Neoplasms mortality, DNA Mismatch Repair, Female, Humans, Male, Middle Aged, Survival Analysis, Antineoplastic Agents therapeutic use, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Microsatellite Instability
Abstract

Background: Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present survival data on a large, comprehensive cohort of dMMR mCRC patients, treated with or without systemic non-immunotherapy., Methods: Two hundred and eighty-one dMMR mCRC patients (n = 54 from three prospective Phase 3 CAIRO trials; n = 227 from the Netherlands Cancer Registry). Overall survival was analysed from diagnosis of mCRC (OS), from initiation of first-line (OS1) and second-line (OS2) systemic treatment. Cox regression analysis examined prognostic factors. As comparison for OS 2746 MMR proficient mCRC patients were identified., Results: Of 281 dMMR patients, 62% received first-line and 26% second-line treatment. Median OS was 16.0 months (13.8-19.6) with antitumour therapy and 2.5 months (1.8-3.5) in untreated patients. OS1 was 12.8 months (10.7-15.2) and OS2 6.2 months (5.4-8.9) in treated dMMR patients. Treated dMMR patients had a 7.6-month shorter median OS than pMMR patients., Conclusion: Available data from immunotherapy trials lack a control arm with standard systemic treatment. Given the poor outcome compared to the immunotherapy results, our data strongly suggest a survival benefit of immunotherapy in dMMR mCRC patients.

Published
2021
Full Text
View/download PDF

33. Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.

Author

Broijl A, Kersten MJ, Alemayehu WG, Levin MD, de Weerdt O, Vellenga E, Meijer E, Wittebol S, Tanis BC, Cornelisse PB, Stevens-Kroef M, Bos GM, Wijermans PW, Lokhorst H, and Sonneveld P

Subjects
Aged, Aged, 80 and over, Drug Administration Schedule, Drug Dosage Calculations, Female, Humans, Lenalidomide, Logistic Models, Male, Maximum Tolerated Dose, Middle Aged, Multiple Myeloma complications, Multiple Myeloma mortality, Multiple Myeloma pathology, Neoplasms, Second Primary complications, Neoplasms, Second Primary mortality, Neoplasms, Second Primary pathology, Recurrence, Survival Analysis, Thalidomide therapeutic use, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bortezomib therapeutic use, Dexamethasone therapeutic use, Multiple Myeloma drug therapy, Neoplasms, Second Primary drug therapy, Thalidomide analogs & derivatives
Published
2016
Full Text
View/download PDF

34. Haplotypes encoding the factor VIII 1241 Glu variation, factor VIII levels and the risk of venous thrombosis.

Author

Nossent AY, Eikenboom JC, Vos HL, Bakker E, Tanis BC, Doggen CJ, Bertina RM, and Rosendaal FR

Subjects
Aged, Case-Control Studies, Female, Haplotypes, Humans, Logistic Models, Male, Middle Aged, Polymorphism, Single Nucleotide, Protein C metabolism, Risk Factors, Sequence Analysis, DNA, Sex Factors, Venous Thrombosis blood, Factor VIII genetics, Factor VIII metabolism, Venous Thrombosis genetics
Abstract

Levels of factor VIII (FVIII) are associated with the risk of venous thrombosis. The FVIII variation D1241E has been reported to be associated with decreased levels of FVIII. Our objective was to study whether D1241E is associated with levels of FVIII and the risk of venous thrombosis and whether this association is caused by D1241E or another linked variation. We analyzed the association of three FVIII gene haplotypes encoding 1241E (further denoted as HT1, HT3, and HT5) with FVIII levels and thrombosis risk. This analysis was performed in the Leiden Thrombophilia Study (LETS). The control populations of two case-controls studies on arterial thrombosis in men and women, respectively, were used to confirm the effects observed on FVIII:C in the LETS. In men, HT1 was associated with a 6% reduction in FVIII:C and with a reduced risk of venous thrombosis [odds ratio 0.4 (CI95 0.2-0.8)]. Logistic regression showed that the risk reduction was only partially dependent of the reduction in FVIII levels. HT1 showed no effects in women on either FVIII:C or risk of thrombosis. The number of carriers of HT3 and HT5 was too low to make an accurate estimate of the risk of venous thrombosis. Neither HT3 nor HT5 showed effects on levels of FVIII:C. When we consider that all three haplotypes encoding 1241E show different effects on FVIII:C and thrombosis risk, it is possible that D1241E is not the functional variation. However, FVIII gene variations do contribute to both levels of FVIII and the risk of thrombosis.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results